SBD Capital (OTC:SBDCF) Stock, Quote.Headers.trade-ideas

SBD Capital Corp operates in Canada. The company acquires controlling interests in industrial companies in the manufacturing and distribution business. It invests in venture and early-stage craft alcohol companies. Its cash-generating unit is alcohol and liquor sales.

SBD Capital Corp

Piper Sandler analyst David Amsellem maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Overweight and raises the price target from $310 to $329.

News

Price Target

Analyst Ratings

AMGN

Piper Sandler Maintains Overweight on Amgen, Raises Price Target to $329

Barclays analyst Brandon Oglenski maintains Hub Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBG#NASDAQ">HUBG</a>) with a Equal-Weight and lowers the price target from $52 to $50.

HUBG

Barclays Maintains Equal-Weight on Hub Group, Lowers Price Target to $50

WIIM

AXSM

Axsome Therapeutics shares are trading higher after the company reached a settlement agreement with Teva Pharmaceuticals resolving all patent litigation related to its Auvelity product.

HYFM

Hydrofarm Holdings shares are trading lower after the company announced its board approved a 1-for-10 reverse stock split.

U.S. stock futures were higher this morning, with the Dow Jones futures gaining <a href="https://www.benzinga.com/quote/TSLA">around 150 points on Monday</a>.
Shares of Tesla, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell in today's <a href="https://www.benzinga.com/quote/TSLA">pre-market trading</a>.
Tesla CEO Elon Musk and Vice President of Finance Sendil Palani addressed allegations of the EV company evading taxes in posts on X over the weekend. The company did not evade tax but carried it forward as per an Internal Revenue Service (IRS) provision, they said.
Tesla shares fell 1.2% to $357.16 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Pliant Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) dipped 54.5% to $3.54 in pre-market trading after the company issued an update on BEACON-IPF, a Phase 2b/3 trial in patients with idiopathic pulmonary fibrosis.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) shares tumbled 25.2% to $40.75 in pre-market trading. Semtech shares fell around 10% on Friday after Baird cut its price target on the stock from $80 to $60.</li>
<li>Oriental Rise Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIS#NASDAQ">ORIS</a>) declined 20.2% to $0.91 in pre-market trading after falling more than 5% on Friday.</li>
<li>Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) fell 19.6% to $11.21 in pre-market trading. Replimune announced inducement grants under Nasdaq Listing Rule 5635(c)(4).     </li>
<li>Maze Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) fell 9.5% to $12.11 in pre-market trading. Maze Therapeutics shares gained around 3% on Friday after the company announced that the first patient has been dosed in the company&#8217;s Phase 2 clinical trial, the HORIZON Study, of MZE829 in patients with APOL1 kidney disease.</li>
<li>Dogness (International) Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOGZ#NASDAQ">DOGZ</a>) fell 6.6% to $33.00 in pre-market trading.</li>
<li>The Manitowoc Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTW#NYSE">MTW</a>) shares dipped 6.4% to $9.12 in pre-market trading.</li>
<li>Option Care Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) fell 6% to $29.13 in pre-market trading.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) fell 3.2% to $125.52 in pre-market trading.</li>
<li>ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) shares declined 2.1% to $50.20 in pre-market trading ahead of quarterly earnings.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43559194/jim-cramer-likes-this-utilities-stock-i-think-youve-got-a-good-one"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43559194/jim-cramer-likes-this-utilities-stock-i-think-youve-got-a-good-one">Jim Cramer Likes This Utilities Stock: &#8216;I Think You&#8217;ve Got A Good One&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

DOGZ

MAZE

OPCH

ORIS

PLRX

REPL

SMTC

TSLA

Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Barclays analyst Brandon Oglenski maintains Frontier Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) with a Overweight and raises the price target from $10 to $14.

ULCC

Barclays Maintains Overweight on Frontier Group Holdings, Raises Price Target to $14

FULL-YEAR 2025 FINANCIAL OUTLOOK
We are raising our full-year 2025 guidance to reflect the strength of our year-to-date financial performance and the accounting impact of Fleet Complete's conversion from Canadian accounting standards to U.S. GAAP.
<ul>
<li>Annual revenue is now expected to exceed $362.5 million, a $10 million increase from our prior guidance of approximately $352.5 million.</li>
<li>Adjusted EBITDA is now expected to exceed $75 million, a $2.5 million increase from our prior guidance of $72.5 million, with both figures inclusive of $5 million in secured annualized run-rate synergies.</li>
</ul>

Earnings

Guidance

AIOT

Powerfleet Raised Its 2025 Outlook: Now Expects Revenue To Exceed $362.5M, Up $10M From Prior $352.5M Guidance And Adjusted EBITDA To Exceed $75M, Up $2.5M From Prior

PLYA

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Tech

ECARX announces Integration Of DeepSeek-R1 Model Into ECARX AutoGPT

Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) will release its fourth-quarter financial results, after the <a href="https://www.benzinga.com/quote/vrtx/earnings">closing bell, on Monday, Feb. 10, 2025.</a>
Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly revenue of $2.78 billion, compared to $2.52 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 30, Vertex Pharmaceuticals announced it secured FDA approval for JOURNAVX. Also, the company announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access CASGEVY.
Vertex Pharmaceuticals shares fell 2.5% to close at $469.32 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Rating</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/VRTX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating and raised the price target from $535 to $550 on Jan. 31, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Wells Fargo analyst Mohit Bansal downgraded the stock from Overweight to Equal-Weight with a price target of $460 on Jan. 30, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Truist Securities analyst Joon Lee maintained a Buy rating and lowered the price target from $550 to $460 on Dec. 23, 2024. This analyst has an accuracy rate of 76%.</li>
<li>JP Morgan analyst Jessica Fye maintained an Overweight rating and cut the price target from $503 to $500 on Dec. 23, 2024. This analyst has an accuracy rate of 63%.</li>
<li>BMO Capital analyst Even Seigerman maintained an Outperform rating and cut the price target from $566 to $520 on Dec. 20, 2024. This analyst has an accuracy rate of 62%.</li>
</ul>
Considering buying VRTX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="626" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10041419/image-73-1024x626.png" alt="" class="wp-image-774084" style="width:543px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10041419/image-73-1024x626.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10041419/image-73-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10041419/image-73-768x469.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10041419/image-73.png 1131w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43559194/jim-cramer-likes-this-utilities-stock-i-think-youve-got-a-good-one">Jim Cramer Likes This Utilities Stock: &#8216;I Think You&#8217;ve Got A Good One&#8217;</a></li>
</ul>

VRTX

Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings

Barclays analyst Adrienne Yih maintains Canada Goose Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#NYSE">GOOS</a>) with a Equal-Weight and lowers the price target from $11 to $10.

GOOS

Barclays Maintains Equal-Weight on Canada Goose Hldgs, Lowers Price Target to $10

PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate. The company reported quarterly sales of $106.429 million which beat the analyst consensus estimate of $99.426 million by 7.04 percent. This is a 44.54 percent increase over sales of $73.635 million the same period last year.

Earnings Beats

PowerFleet Q3 2024 Adj. EPS $0.01, Inline, Sales $106.429M Beat $99.426M Estimate

-Data from KONFIDENT-S show patients on LTP average 1.7 HAE attacks per month and symptom relief for treated attacks in median 1.3 hours -
–Results confirm sebetralstat effective for on-demand treatment of attacks regardless of type of LTP therapy used, including an all-oral regimen.

KALV

KalVista Presents New Sebetralstat Data; Claims Data Show 40% Of Patients On Long-term Prophylaxis Have Gaps In Prescription Refills, Leading To Greater On-demand Use And Higher Rate Of LTP Discontinuation

Piper Sandler analyst Adam Maeder maintains Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) with a Overweight and lowers the price target from $260 to $233.

INSP

Piper Sandler Maintains Overweight on Inspire Medical Systems, Lowers Price Target to $233

Laidlaw &amp; Co. analyst Yale Jen initiates coverage on Lifeward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFWD#NASDAQ">LFWD</a>) with a Buy rating and announces Price Target of $10.

Initiation

LFWD

Laidlaw & Co. Initiates Coverage On Lifeward with Buy Rating, Announces Price Target of $10

Tilray's primary Canadian production facilities, Aphria One and Aphria Diamond, are now fully planted and positioned to capture the growing demand from Canadian and International cannabis markets. Certain sections of Aphria One, which were previously idled during the COVID-19 pandemic, are now back online.

Cannabis

General

TLRY

Tilray Brands Completed Phase 1 Of Its Accelerated Growth Plan For Its Cannabis Supply Chain, Which Began With Increased Planting In Late 2024, Phase 2 Of The Growth Plan Includes Planting The Outdoor Cultivation Site In Cayuga This Spring

UEIC

Universal Electronics  Announces Collaboration With Somfy For Wireless Remote Control And Sensor Products

The earnings results for Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) for Q4 were made public on Monday, February 10, 2025 at 07:00 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Incyte missed estimated earnings by -8.0%, reporting an EPS of $1.43 versus an estimate of $1.55.
Revenue was up $166.00 million from the same period last year.
<h3>Overview of Past Earnings</h3>
Last quarter the company missed on EPS by $0.02 which was followed by a 0.0% increase in the share price the next day.
Here's a look at Incyte's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.09</td>
<td>-1.55</td>
<td>0.84</td>
<td>1.16</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.07</td>
<td>-1.82</td>
<td>0.64</td>
<td>1.06</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.08B</td>
<td>1.01B</td>
<td>926.53M</td>
<td>1.00B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.14B</td>
<td>1.04B</td>
<td>880.89M</td>
<td>1.01B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Incyte <a href="https://www.benzinga.com/quote/INCY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INCY

Insights into Incyte Q4 Earnings

MNDY: 20% &#x7C; <a href="https://www.benzinga.com//node/43588603">Monday.com share are trading higher after the company reported better-than-expected Q4 financial results and Q1 revenue outlook.</a>
&nbsp;
ORN: 8% &#x7C; <a href="https://www.benzinga.com//node/43588969">Orion Group shares are trading higher after the company secured new marine and concrete awards totaling approximately $211.7 million.</a>
&nbsp;
ROK: 9% &#x7C; <a href="https://www.benzinga.com//node/43588987">Rockwell Automation shares are trading higher after the company reported Q1 earnings above estimates.</a>

MNDY

Market-Moving News for February 10th

Hain Celestial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>) just disclosed its Q2 earnings on Monday, February 10, 2025 at 07:00 AM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Hain Celestial Group missed estimated earnings by -33.0%, reporting an EPS of $0.08 versus an estimate of $0.12.
Revenue was down $42.62 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company missed on EPS by $0.02 in the previous quarter, leading to a 1.0% drop share price change the next day.
Here's a look at Hain Celestial Group's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.02</td>
<td>0.08</td>
<td>0.07</td>
<td>0.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.04</td>
<td>0.13</td>
<td>0.13</td>
<td>0.12</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>394.32M</td>
<td>421.21M</td>
<td>463.39M</td>
<td>462.05M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>394.60M</td>
<td>418.80M</td>
<td>438.36M</td>
<td>454.10M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Hain Celestial Group <a href="https://www.benzinga.com/quote/HAIN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

SBD Capital

SBD Capital (OTC:SBDCF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga